IT'S IMPORTANT TO KEEP UP WITH YOUR TREATMENT SCHEDULE
The recommended dose of EYLEA for RVO is 2 mg administered
by injection in the eye once every 4 weeks (approximately
every 25 days, monthly).
Your eye care team will want to see you regularly to check
your vision and also check your treatment progress with
EYLEA. Work with your eye care team to make sure you can
keep your appointments and stay on your recommended
Safety information for EYLEA
EYLEA® (aflibercept) Injection is a prescription medicine
administered by injection into the eye. You should not use
EYLEA if you have an infection in or around the eye, eye
pain or redness, or known allergies to any of the
ingredients in EYLEA, including aflibercept.
Injection into the eye with EYLEA can result in an
infection in the eye and retinal detachment (separation of
retina from back of the eye). Inflammation in the eye has
been reported with the use of EYLEA.
In some patients, injections with EYLEA may cause a
temporary increase in eye pressure within 1 hour of the
injection. Sustained increases in eye pressure have been
reported with repeated injections, and your doctor may
monitor this after each injection.
There is a potential risk of serious and sometimes fatal
side effects related to blood clots, leading to heart
attack or stroke in patients receiving EYLEA.
Serious side effects related to the injection procedure
with EYLEA are rare but can occur including infection
inside the eye and retinal detachment.
The most common side effects reported in patients
receiving EYLEA are increased redness in the eye, eye
pain, cataract, vitreous (gel-like substance) detachment,
vitreous floaters, moving spots in the field of vision,
and increased pressure in the eye.
As with all therapeutic proteins, there is a potential for
an immune response in patients treated with EYLEA.
It is important that you contact your doctor right away if
you think you might be experiencing any side effects,
including eye pain or redness, light sensitivity, or
blurring of vision, after an injection.